Skip to main content

Table 1 Logistic regression assessing correlation between PTC GL-3 reductions and GSRS-D improvement (patients with amenable mutations)

From: Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial

Parameter and Criteria Odds Ratio 95% CI of Odds Ratio
GSRS-D Reduction From Baseline of 0.33 (n = 50) 5.55 (1.17–26.26)
p = .031
Kidney Peritubular Capillary GL-3 Reduction From Baseline > 0.1
  1. CI confidence interval, GL-3 globotriaosylceramide, GSRS-D Gastrointestinal Symptoms Rating Scale—diarrhea